A Unique Biomarker Hiding In Plain SightWORLD-FIRST DETECTION TECHNOLOGY
It recently became clear that cells shed from sprouting cancer blood vessels into the main blood circulation in significant numbers[1,2].
Hailed as a “truly novel biomarker” for cancer, these so-called tumour-derived Circulating Endothelial Cells (CEC) are extremely difficult to detect because they are morphologically similar to healthy blood cells.
X-ZELL, however, found a way to isolate and characterize CEC at the single cell level, using our unique multi-marker detection technology.
CEC provide a wealth of information that current clinically approved liquid biopsies cannot deliver on. The result is a world-first approach that could revolutionise cancer cell detection as we know it.
Why are CEC so valuable?
- CEC shed from earliest stage cancers and could help us detect cancer early when it can be cured.
- CEC shed from smallest tumour sizes (1 mm), making them ultra-sensitive to the disease .
- CEC show the highest prevalence of all cell-based cancer markers, making them the ideal “point of attack” for cancer detection.
Why are CEC hard to find?
- CEC exhibit extensive antigen overlap with white blood cells, blood stem cells and healthy endothelial cells, making them extremely hard to differentiate.
- CEC cannot be isolated by targeting a single marker – they require the removal of healthy blood cells.
- The characterization of CEC requires advanced multiplexing of immunostaining, a technology exclusive to X-ZELL.
 Cima et al., Science Translational Medicine; 8(345):345ra89. (2016)
 Lin et al., Scientific Reports; 7(1):9789. (2017)
 Bhakdi et al. , Manuscript submitted (2017)
 Dudley. Cold Spring Harbor Perspectives in Medicine 2(3):1–18. (2012)
Get In Touch
Use the form below to contact us for more information.